7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepine-2-thione | 41282-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepine-2-thione
• 英文别名: 7-chloro-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepine-2-thione
• CAS: 41282-00-2
• 化学式: C₁₆H₁₃ClN₂S
• 分子量: 300.812
• InChiKey: WPCGECBGZJGQIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepine-2-thione 在 溶剂黄146 、 乙酰氯 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 2.0h， 生成 8-chloro-N,N,4-trimethyl-β,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1-ethanamine
  参考文献：
  名称：

  1-(2-Aminoethyl)-6-aryl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity

  摘要：

  A series of 1-(2-amino-1-phenylethyl)-6-phenyl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines was prepared and evaluated for diuretic activity. These compounds have diuretic and natriuretic activity but no kaliuretic activity when evaluated by oral administration to the conscious rat. The structure requirements for this activity are discussed. In particular it was found that the 2-aminoethyl side chain at C-1 with hydrogen or methyl substituents on the amino group was required for diuretic activity. A substituent at C-8 was also required; soft substituents such as methylthio and iodo at this position favored activity. Compounds with both phenyl and 2-pyridyl substituents at C-6 were active; substituents on the C-6 phenyl, however, reduced or eliminated the activity. Substituents other than phenyl at the 1-position of the 2-aminoethyl side chain were detrimental to activity; phenyl substitution at this position was required for activity when the substituent at C-8 was chloro but not when it was bromo.

  DOI：

  10.1021/jm00126a003
• 作为产物：
  描述：

  7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 在 tetraphosphorus decasulfide 作用下， 以 吡啶 为溶剂， 反应 3.0h， 以61.3%的产率得到7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepine-2-thione
  参考文献：
  名称：

  1-（氨基烷基）-6-芳基-4-Hs-三唑并[4,3-a] [1,4]苯并二氮杂卓具有抗焦虑和抗抑郁活性。

  摘要：

  已经制备了一系列的1-（氨基烷基）-6-芳基-4H-s-三唑并[4，3-a] [1，4]苯并二氮杂并评估中枢神经系统活性。我们发现该系列的成员在旨在检测抗焦虑和抗抑郁活性的药理学测试系统中具有活性。每种类型的活性可以通过适当的取代基选择独立地变化。

  DOI：

  10.1021/jm00178a009

文献信息

• 2-(2-Alkynylamino)-3H-1,4-benzodiazepines
  申请人：The Upjohn Company

  公开号：US03933794A1

  公开（公告）日：1976-01-20

  Novel 6-substituted 4H-imidazo[1,2-a][1,4]benzodiazepines, the intermediate 5-substituted-2-(2-alkynylamino)-3H-1,4-benzodiazepines, pharmacologically acceptable acid addition salts thereof, and processes for their production. The compounds of this invention and the pharmacologically acceptable acid addition salts thereof are central nervous system depressants. They are useful as sedatives, hypnotics, tranquilizers, muscle relaxants and anticonvulsants, and also as feed additives for increasing growth rate and feed efficiency of livestock and poultry, milk production in the mammalian species and egg production in avian species.

  新型6-取代的4H-咪唑[1,2-a][1,4]苯二氮杂环己烷，中间体5-取代的2-(2-炔基氨基)-3H-1,4-苯二氮杂环己烷，其药理学上可接受的酸盐，以及它们的生产工艺。本发明的化合物及其药理学上可接受的酸盐是中枢神经系统抑制剂。它们可用作镇静剂、催眠药、镇定剂、肌肉松弛剂和抗惊厥剂，还可作为增加家畜和家禽生长速度和饲料效率、哺乳动物种类的产奶量和禽类种类的产蛋量的饲料添加剂。
• Triazolo-benzodiazepine-1-ethanamines as diuretics
  申请人：The Upjohn Company

  公开号：US04689413A1

  公开（公告）日：1987-08-25

  Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ring A are as defined in the specification, e.g., 8-chloro-N,N-dimethyl-.beta.,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolol, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.

  公式为##STR1##的Triazolo-benzodiazepine-1-ethanamines，其中R，R.sub.1，R.sub.2，R.sub.3，R.sub.4和环A的定义如规范中所述，例如8-氯-N，N-二甲基-β，6-二苯基-4H-[1，2，4]三唑[4，3-a][1,4]苯并二氮平-1-乙胺及其药理学上可接受的盐，已发现具有显著的利尿、钠利尿作用，但几乎没有钾利尿作用，可单独使用，或与其他利尿药物如呋塞米或氢氯噻嗪和/或降压药物如普萘洛尔、卡托普利、米诺地尔、普拉索辛、磺酸冠脲等同时使用，这些药物的作用通过利尿药物的作用得到补充。
• 1-Ethanamine-triazolo-benzodiazepines as diuretics
  申请人：The Upjohn Company

  公开号：US04514407A1

  公开（公告）日：1985-04-30

  Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ring A are as defined in the specification, e.g., 8-chloro-N,N-dimethyl-.beta.,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolo, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.

  公式为##STR1##的Triazolo-benzodiazepine-1-ethanamines，其中R、R.sub.1、R.sub.2、R.sub.3、R.sub.4和Ring A的定义如规范中所述，例如8-氯-N，N-二甲基-β，6-二苯基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮平-1-乙胺，及其药理学上可接受的盐，已被发现具有显著的利尿、钠利尿作用，但很少有钾利尿作用，可以单独使用，或与其他利尿药物如呋塞米或氢氯噻嗪和/或抗高血压药物如普萘洛尔、卡托普利、米诺地尔、哌唑嗪、磺酸冠脲和其他利尿药物的作用相辅相成。
• 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases
  申请人：Hoffmann-La Roche Inc.

  公开号：US11021448B2

  公开（公告）日：2021-06-01

  The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

  本发明提供的化合物是毒蕈碱 M1 受体正性异位调节剂 (PAM)，可用于治疗由毒蕈碱 M1 受体介导的疾病，如阿尔茨海默氏症、认知障碍、精神分裂症、疼痛或睡眠障碍；本发明还提供了这些化合物的制造方法、含有这些化合物的药物组合物及其作为治疗活性物质的用途。
• HESTER J. B.; RUDZIK A. D.; VOIGTLANDER P. F. VON, J. MED. CHEM., 1980, 23, NO 4, 392-402
  作者：HESTER J. B.、 RUDZIK A. D.、 VOIGTLANDER P. F. VON

  DOI：——

  日期：——